Actively Recruiting
Clinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)
Led by Chelyabinsk Regional Clinical Hospital · Updated on 2024-09-19
56
Participants Needed
1
Research Sites
491 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to evaluate early safety, clinical efficacy and long-term outcomes of mitral allografts and stented biological prosthesis in tricuspid valve replacement for primary tricuspid valve diseases.
CONDITIONS
Official Title
Clinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failure scheduled for tricuspid valve intervention
- Intraoperative findings suggesting tricuspid valve replacement rather than repair
- Age between 18 and 70 years
You will not qualify if you...
- Pregnancy
- Confirmed active drug addiction
- Progressive HIV infection
- HIV-infected patients with CD4 cell count less than 250
- Patients with secondary tricuspid valve pathology (left-sided valve disease)
- Left ventricular ejection fraction less than 40%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Cardiac Surgery
Chelyabinsk, Russia
Actively Recruiting
Research Team
M
Mikhail Nuzhdin, PhD
CONTACT
Y
Yuri Malinovsky, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here